The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

In 2021, aducanumab was the first FDA-approved therapy that targeted the biology but is set to be discontinued on Friday due to the manufacturer Biogen "reprioritizing its resources in Alzheimer's ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual ...

Biogen's phase 3 Alzheimer's program for aducanumab was halted in March 2019 and produced mixed data. While the drug was approved in the US in June 2021, it has been a commercial failure.

Biogen has insisted that it will continue to make “big bets” on novel drugs – and early trial results for its aducanumab suggest it may be on the right track. Earlier this year, global ...